HOME >> BIOLOGY >> NEWS
Over the edge: New therapeutic strategy takes advantage of stressed cancer cells

A biochemical alteration that has long been viewed as an adverse aspect of tumor biology may turn out to be a deadly double-edged sword for the cancer cells themselves. Scientists have successfully exploited the oxidative stress common in cancer cells to preferentially kill malignant cells. This approach has the therapeutic advantage of selectively targeting cancer cells while exhibiting minimal toxicity in normal cells. The research is published in the September 2006 issue of the journal Cancer Cell, published by Cell Press.

Most cancer cells exhibit overproduction of reactive oxygen species (ROS), which is thought to provide favorable conditions for cancer cell growth, genetic instability, and survival. Dr. Peng Huang from the Department of Molecular Pathology at the University of Texas M.D. Anderson Cancer Center and colleagues hypothesized that increased ROS generation may also make cancer cells highly vulnerable to exogenous ROS-modulating agents that would not be toxic to normal cells with low ROS output.

The researchers examined the ability of a naturally occurring compound called -phenylethyl isothiocyanate (PEITC), which is known to modulate cellular antioxidant pathways, to push cancer cells to even higher ROS levels that result in cell death. Oncogenically transformed cells exhibited high basal ROS levels and were more sensitive to PEITC than nontransformed cells. PEITC interfered with a specific antioxidant system that the cancer cells relied on to maintain a ROS balance that was compatible with survival. Treatment with PEITC led to further ROS accumulation that caused massive death of cancer cells but no cytotoxicity in normal cells. Importantly, PEITC also significantly prolonged survival in an animal model of human cancer.

"Our study suggests that the intrinsic oxidative stress in cancer cells associated with oncogenic transformation provides a basis for developing therapeutic strategies to preferentially kill cancer cell
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
11-Sep-2006


Page: 1 2

Related biology news :

1. On the cutting edge: Carbon nanotube cutlery
2. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
3. From clinical cancer research: rethinking therapeutic cancer vaccine trials
4. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
5. New therapeutic insight into duchenne muscular dystrophy
6. Small molecule derived from Rb2/p130 could act as cancer therapeutic
7. Sphingolipids with therapeutic ends
8. New therapeutic target for Alzheimers could lead to drugs without side effects
9. VBI research offers potential route to diabetes therapeutics
10. Quiet revolution may herald new RNA therapeutics
11. Scientists discover two-component lantibiotic with therapeutic potential

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... Mitotech ... partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in Ophthalmology and Dermatology, ... of SkQ1 ophthalmic solution in patients with moderate to severe Dry Eye ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage ... Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) ... severe COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... Princeton, NJ, have entered into license agreements with Housey Pharma’s HMI subsidiary to ... Roche and J&J have annual Research and Development spending in excess of US ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., ... hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of ...
(Date:7/1/2020)... ... June 29, 2020 , ... MedShift , a leading ... despite many obstacles created as a result of COVID-19. As a provider at ... medical practices and medical manufacturers by expanding access to device offerings, technology services, ...
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a leading provider of sensor ... of all types to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ ... enabled business will provide a health performance index system that scores all aspects of ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... security solutions providers, today announced its strong opposition to the recently introduced bicameral ... impose a blanket ban on most federal use of nearly all biometric and ...
Breaking Biology Technology:
Cached News: